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The P2Y12 Antagonists, 2MeSAMP and Cangrelor, Inhibit
Platelet Activation through P2Y12/Gi-Dependent
Mechanism
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Kent Gartner2, Susan S. Smyth1,3, Zhenyu Li1*
1 Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America, 2Department of Biology, University of
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Abstract
Background: ADP is an important physiological agonist that induces integrin activation and platelet aggregation through
its receptors P2Y1 (Gaq-coupled) and P2Y12 (Gai-coupled). P2Y12 plays a critical role in platelet activation and thrombosis.
Adenosine-based P2Y12 antagonists, 2-methylthioadenosine 59-monophosphate triethylammonium salt hydrate (2MeSAMP)
and Cangrelor (AR-C69931MX) have been widely used to demonstrate the role of P2Y12 in platelet function. Cangrelor is
being evaluated in clinical trials of thrombotic diseases. However, a recent study reported that both 2MeSAMP and
Cangrelor raise intra-platelet cAMP levels and inhibit platelet aggregation through a P2Y12-independent mechanism.
Methodology/Principal Findings: The present work, using P2Y12 deficient mice, sought to clarify previous conflicting
reports and to elucidate the mechanisms by which 2MeSAMP and Cangrelor inhibit platelet activation and thrombosis.
2MeSAMP and Cangrelor inhibited aggregation and ATP release of wild-type but not P2Y12 deficient platelets. 2MeSAMP
and Cangrelor neither raised intracellular cAMP concentrations nor induced phosphorylation of vasodilator-stimulated
phosphoprotein (VASP) in washed human or mouse platelets. Furthermore, unlike the activators (PGI2 and forskolin) of the
cAMP pathway, 2MeSAMP and Cangrelor failed to inhibit Ca2+ mobilization, Akt phosphorylation, and Rap1b activation in
P2Y12 deficient platelets. Importantly, while injection of Cangrelor inhibited thrombus formation in a FeCl3-induced
thrombosis model in wild-type mice, it failed to affect thrombus formation in P2Y12 deficient mice.
Conclusions: These data together demonstrate that 2MeSAMP and Cangrelor inhibit platelet function through the P2Y12-
dependent mechanism both in vitro and in vivo.
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Introduction
Platelets play a key role in hemostasis. Platelet activation
includes a series of positive feedback loops that rapidly amplify
activation signals to enable robust platelet recruitment and
stabilization of thrombi at the sites of vascular injury. Two
important mechanisms for amplification are the release of granule
cargo (mainly ADP) and synthesis of TXA2 from cyclooxygenase 1
(COX1) signaling. Granule cargo release is required for full
platelet responses induced by weak agonists or low concentrations
of strong agonists. One of the important substances secreted from
dense granules is ADP, which induces integrin activation and
platelet aggregation through its receptors, P2Y1 and P2Y12 [1].
P2Y1 couples to Gaq (Gq) that transmits cellular signals mainly
through its interaction and stimulation of phospholipase Cb
(PLCb) [2]. Activation of PLCb results in generation of inositol
trisphosphate (IP3) and diacyl glycerol (DAG) that elicit calcium
release and protein kinase C (PKC) activation, respectively [3].
P2Y12 couples to Gai (Gi) family members [4,5], primarily by
coupling to Gi2 [6,7]. Activation of Gi downstream from P2Y12
inhibits cAMP accumulation and induces activation of the small
GTPase Rap1b in a phosphoinositide 3-kinase (PI3K)-dependent
manner.
Mice lacking P2Y12 exhibit highly prolonged bleeding times and
impaired thrombus formation [5,8]. P2Y12 deficient patients have
increased bleeding times and abnormal platelet aggregation and
secretion, probably due to abnormal cAMP regulation [9,10].
Antiplatelet therapies targeting P2Y12, such as clopidogrel,
ticagrelor, and prasugrel, have proven benefit in preventing or
treating acute arterial thrombosis, and novel P2Y12 inhibitors are
still in development [11,12,13,14]. P2Y12 is required for ADP-
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induced platelet activation, and also contributes to platelet
activation induced by other platelet agonists, such as thrombin
and thromboxane A2 (TXA2) [8,15]. Evidence supporting this
notion comes not only from patients and mice lacking functional
P2Y12, but also from the use of the adenosine-based P2Y12
antagonists, 2MeSAMP and Cangrelor [8,10,16,17,18]. However,
a recent study reported that both 2MeSAMP and Cangrelor
significantly increase intra-platelet cAMP levels in a P2Y12/Gi-
independent manner [19]. Thus, these findings raise a question
not only about the specificity of these P2Y12 antagonists, but also
about the role of P2Y12 in platelet activation.
Our data from studies using human platelets and P2Y12
deficient mice demonstrate that both 2MeSAMP and Cangrelor
do not significantly raise cAMP levels, nor induce vasodilator-
stimulated phosphoprotein (VASP) phosphorylation in platelets.
Furthermore, 2MeSAMP and Cangrelor inhibit platelet aggrega-
tion and in vivo thrombosis only in wild-type mice, but not in
P2Y12 deficient mice. Taken together, the results therefore
indicate that these adenosine-based P2Y12 antagonists inhibit
platelet function through the P2Y12-dependent mechanism.
Materials and Methods
Materials
a-Thrombin was purchased from Enzyme Research Laborato-
ries (South Bend, IN). PAR 4 peptide AYPGKF was custom-
synthesized at Biomatik USA, LLC (Wilmington, DE). FeCl3,
ADP, and 2MeSAMP were from Sigma. Luciferase/luciferin
reagent was from Chrono-log (Havertown, PA). Forskolin was
purchased from Calbiochem (San Diego, CA). Fura-2/AM and
Pluronic F-127 were from Invitrogen (Carlsbad, CA, USA).
RalGDS-RBD fused to GST was a generous gift from Dr.
Johannes L. Bos, University Medical Center, Utrecht, the
Netherlands. Mouse monoclonal antibodies against VASP phos-
phorylated at residues serine 157 or serine 239 were purchased
from Santa Cruz Biotechnology Inc. Rabbit monoclonal anti-
bodies against the phosphorylated Ser473 or Thr308 residues of Akt
were from Cell Signaling Technology (Beverly, MA). cAMP
ELISA kit was from Amersham Biosciences.
Animals
P2Y12 deficient mice were generated as described previously
[5]. Littermate wild-type mice from heterozygous breeding were
used as controls. All animal procedures were conducted in
accordance with appropriate regulatory standards approved by
the animal research committee at University of Kentucky,
following institutional guidelines for the proper and humane use
of animals in research.
Preparation of Platelets
Washed mouse platelets were prepared as described previously
[8]. Platelets were resuspended in modified Tyrode’s buffer
(12 mM NaHCO3, 138 mM NaCl, 5.5 mM glucose, 2.9 mM
KCl, 2 mM MgCl2, 0.42 mM NaH2PO4, 10 mM HEPES,
pH 7.4) at 36108/ml, and incubated for 1 h at 22uC before use.
Washed human platelets were prepared as described previously
[8], and resuspended in modified Tyrode’s buffer. All participants
were provided with written informed consent, and the study was
approved by the research ethics boards at University of Kentucky.
Platelet Aggregation and Secretion
Platelet aggregation at 37uC was measured by detecting changes
in light transmission using a turbidometric platelet aggregometer
(Chrono-Log) with stirring (1000 rpm). Platelet secretion was
determined by measuring the release of ATP using luciferin/
luciferase reagent. Luciferin/luciferase reagent (12 ml) was added
to 238 ml of a washed platelet suspension 1 min before stimulation.
Western Blot Analysis of Akt and VASP Phosphorylation
in Platelets
Washed platelets (36108/ml) were preincubated with Cangrelor
(1 mM), 2MeSAMP (10 mM), or forskolin (10 mM) for 5 min, and
then stimulated with thrombin or AYPGKF in a platelet
aggregometer at 37uC for 5 min and then solubilized in SDS-
PAGE sample buffer. Platelet lysates were analyzed by SDS-
PAGE on 4–15% gradient gels and immunoblotted using rabbit
monoclonal antibodies specific for the phosphorylated Akt residues
Ser473 or Thr308 [20]. To detect VASP phosphorylation, washed
platelets were incubated with Cangrelor, 2MeSAMP, or forskolin
at 37uC for 5 min. VASP phosphorylation was analyzed by
Western blot as described previously [8].
Determination of Intracellular cAMP Levels
Washed platelets (36108/ml) from healthy donors, P2Y12
deficient or wild-type mice were resuspended in Tyrode’s solution
and incubated with 2MeSAMP, Cangrelor, or forskolin for 5 min
at 37uC. The reaction was stopped by addition of an equal volume
of ice-cold 12% (wt/vol) trichloroacetic acid. Samples were mixed
and centrifuged at 2000 g for 15 minutes at 4uC. Each supernatant
fraction was washed with 5 volumes of water-saturated diethyl
ether 4 times and then lyophilized. cAMP levels were measured
using a cAMP enzyme immunoassay kit [8].
To measure intra-platelet cAMP concentrations by mass
spectrometry, cAMP was extracted from platelets (36108) by
using a mixture of 3:2 ice-cold acetonitrile and water. 29
Deoxyadenosine 39, 59-cyclic monophosphate (2-dAcAMP) from
Sigma Aldrich was used as an internal standard. The supernatant
fraction containing cAMP was evaporated to dryness under N2
after centrifugation at 20,000 g for 30 min at 4uC, and recon-
stituted with 1:1 acetonitrile and water. cAMP was quantitated by
HPLC- electrospray ionization (ESI) tandem mass spectrometry
using an AB Sciex (Foster City, CA) 4000 Q-Trap hybrid linear
ion trap triple-quadrupole mass spectrometer equipped with
a Turbo V electrospray ion source. cAMP and 2-dAcAMP were
analyzed on a Kinetex PFP, 10064.6 mm, 2.6 u column from
Phenomenex with 0.1% formic acid in water and 0.1% formic
acid in acetonitrile as solvents at a flow rate of 0.5 mL/min. The
mass spectrometer was operated in the positive ESI mode
monitoring the following MRM transitions: 314.13/135.9 and
314.13/118.9 for 2-dAcAMP; 330.21/136 and 330.21/118.9 for
cAMP. Recovery was calculated using the internal standard and
cAMP levels were determined using an off line calibration and
normalized to platelet counts [21].
Rap1b Activation
Washed platelets (36108/ml) from P2Y12 deficient mice were
pre-incubated with 2MeSAMP (10 mM), Cangrelor (1 mM), or
forskolin (10 mM) for 5 min, and then stimulated with thrombin
(0.25 U/ml) or AYPGKF (500 mM) for an additional 5 min at
37uC with stirring. Rap1b activation was measured as described
previously [22].
Ca2+ Mobilization
Intra-platelet Ca2+ was measured using Fura-2/AM as de-
scribed previously [22]. Labeled platelets were preincubated with
Cangrelor (1 mM), 2MeSAMP (10 mM), forskolin (10 mM), or
PGI2 (1 mM).
P2Y12 Antagonists Inhibit Platelet Activation
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In vivo Thrombosis
An in vivo thrombosis model was performed as described
previously [23]. 20% of FeCl3 was applied to a filter paper disc
that was immediately placed on top of the artery for 3 minutes.
Cangrelor (4 mg per mouse) or saline was injected into the fundus
oculi of the mice 5 min prior to the initiation of carotid artery
injury.
Statistics
Statistical significance was determined using a Student t test.
Bar charts show mean 6 standard deviation (SD). Fisher exact test
was used for analysis of the in vivo thrombosis model. A p-value of
less than 0.05 was considered significant.
Results
2MeSAMP and Cangrelor Inhibit Platelet Activation
through P2Y12
In order to determine whether inhibition of platelet activation
by 2MeSAMP and Cangrelor is mediated specifically through
P2Y12, the effects of 2MeSAMP and Cangrelor on platelet
aggregation and secretion of ATP were examined. cAMP-de-
pendent protein kinase (PKA) is a strong inhibitory signaling
pathway of platelet activation. As expected, the PKA pathway
activators, forskolin and PGI2, respectively inhibited aggregation
and ATP secretion in both wild-type (Fig. 1A) and P2Y12 deficient
platelets (Fig. 1B) in response to the thrombin receptor PAR4
activator, the peptide AYPGKF. In contrast, 2MeSAMP and
Cangrelor inhibited aggregation and ATP release in wild-type
platelets elicited only by low concentrations of AYPGKF (Fig. 1C).
Similar to 2MeSAMP and Cangrelor treatment, aggregation and
secretion were reduced in P2Y12 deficient platelets in response to
low-dose AYPGKF (Fig. 1C), but not to high-dose AYPGKF
(Fig. 1D). Unlike forskolin and PGI2, 2MeSAMP and Cangrelor
did not affect aggregation and secretion of P2Y12 deficient platelets
(Fig. 1C and 1D). These results not only demonstrate a role of the
Gi pathway activated by ADP through P2Y12 in platelet activation
in response to low-dose AYPGKF, but also indicate that the effects
of 2MeSAMP and Cangrelor on platelet aggregation and secretion
are P2Y12-dependent. ADP failed to stimulate aggregation and
secretion of P2Y12 deficient platelets and 2MeSAMP- or
Cangrelor-treated platelets (data not shown).
2MeSAMP and Cangrelor Failed to Stimulate cAMP
Production in Platelets
In contrast to a previous report showing that 2MeSAMP and
Cangrelor increase intra-platelet cAMP concentrations through
a P2Y12-independent mechanism [19], we found that Cangrelor,
up to 1 mM, failed to increase intracellular cAMP levels in human
or mouse platelets (Fig. 2A and 2B). As a positive control, forskolin
markedly increased intra-platelet cAMP concentrations (Fig. 2A
and 2B). While 2MeSAMP at concentrations at or below 10 mM
did not increase cAMP levels in human platelets, it apparently
increased intra-platelet cAMP levels at a higher concentration
(50 mM) (Fig. 2A). Surprisingly, 2MeSAMP at 50 mM ‘enhanced’
cAMP concentrations in Tyrode’s solution in the absence of
platelets. These results suggest that 2MeSAMP may cross-react
with the cAMP ELISA assay, thereby causing false positive results.
2MeSAMP at concentrations at or below 10 mM did not increase
cAMP levels in platelets from wild-type or P2Y12 deficient mice
(Fig. 2B). Due to the fact that 2MeSAMP at high concentrations
(.50 mM) interferes with the cAMP ELISA assay, we did not test
high concentrations of 2MeSAMP in mouse platelets.
To further determine whether 2MeSAMP and Cangrelor can
stimulate cAMP production in platelets, we developed an HPLC
electrospray ionization tandem mass spectrometry method to
measure cAMP concentrations. 2MeSAMP (50 mM) or Cangrelor
(1 mM) failed to enhance cAMP levels in mouse platelets or
Tyrode’s solution, as measured by this mass spectrometry-based
assay (Fig. 2C). Using this assay we observed that forskolin
stimulated cAMP production in platelets but not in solution in the
absence of platelets.
2MeSAMP and Cangrelor Failed to Stimulate VASP
Phosphorylation
VASP is a well-known substrate for PKA [8,24,25]. Stimulation
of platelets with forskolin induced VASP phosphorylation in
human platelets (Fig. 3A). Thus, if 2MeSAMP and Cangrelor
increase intracellular cAMP levels in platelets, they should also be
able to induce VASP phosphorylation. However, neither 2Me-
SAMP nor Cangrelor, even at high concentrations, induced VASP
phosphorylation in human platelets (Fig. 3A). 2MeSAMP and
Cangrelor, respectively failed to induce VASP phosphorylation in
both wild-type and P2Y12 deficient mouse platelets (Fig. 3B and
3C). These results indicate that 2MeSAMP and Cangrelor are
unable to activate the cAMP pathway through a P2Y12-in-
dependent mechanism in platelets.
Forskolin and PGI2, but not 2MeSAMP and Cangrelor,
Inhibited AYPGKR-elicited Ca2+ Mobilization
PGE1, by activating Gs-coupled receptors and increasing the
generation of the intracellular cAMP, inhibited platelet activation
in both wild-type and VASP deficient mice [26], demonstrating
that cAMP/PKA signaling inhibits platelet activation through
a VASP-independent mechanism. Stimulation of platelets with
thrombin or TXA2 induces Ca
2+ elevation through Gq-dependent
activation of PLC b. To determine whether or not PKA inhibition
of platelet activation involves the PLC b/Ca2+ signaling, the effect
of PGI2 and forskolin on AYPGKF-elicited Ca
2+ elevation was
examined. AYPGKF-induced Ca2+ mobilization was abolished by
PGI2 and forskolin, respectively (Fig. 4). In contrast, 2MeSAMP
and Cangrelor did not affect AYPGKF-elicited Ca2+ elevation in
P2Y12 deficient platelets, supporting and extending our previous
observation that, unlike PGI2 and forskolin, 2MeSAMP and
Cangrelor cannot activate the cAMP pathway through a P2Y12-
independent mechanism in platelets.
Forskolin, but not 2MeSAMP and Cangrelor, Inhibited Akt
Phosphorylation in P2Y12 Deficient Platelets
Akt phosphorylation in response to thrombin receptor stimu-
lation involves both P2Y12-dependent and -independent mechan-
isms [20]. The effect of 2MeSAMP and Cangrelor on AYPGKF-
induced Akt phosphorylation appears to be specifically mediated
through the P2Y12-dependent pathway, because although 2Me-
SAMP and Cangrelor reduced AYPGKF-induced Akt phosphor-
ylation in wild-type platelets (data not shown), they failed to inhibit
Akt phosphorylation in P2Y12 deficient platelets in response to
thrombin (Fig. 5A) or AYPGKF (Fig. 5B). In contrast, forskolin
abolished Akt phosphorylation in P2Y12 deficient platelets elicited
by thrombin (Fig. 5A) or AYPGKF (Fig. 5B).
Forskolin, but not 2MeSAMP and Cangrelor, Inhibited
AYPGKF-elicited Rap1b Activation in P2Y12 Deficient
Platelets
Rap1b plays important roles in integrin inside-out signaling,
and platelet aggregation [22,27]. P2Y12/Gi signaling is critical for
P2Y12 Antagonists Inhibit Platelet Activation
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Figure 1. 2MeSAMP and Cangrelor inhibit platelet aggregation and secretion through P2Y12-dependent mechanism. (A-B) Washed
platelets from wild-type mice (A) or P2Y12 deficient mice (B) were pre-incubated with PGI2 (1 mM) or forskolin (10 mM) at 37uC for 5 min, and added
with AYPGKF 250 mM to induce ATP release and aggregation. (C–D) Washed platelets (36108/ml) from P2Y12 deficient mice and littermate wild-type
controls were pre-incubated with Cangrelor (1 mM) (Can) or 2MeSAMP (10 mM) (2Me) at 37uC for 5 min, and added with AYPGKF 60 mM (C) or 250 mM
(D) to induce ATP release and aggregation. Data shown are representative of three independent experiments.
doi:10.1371/journal.pone.0051037.g001
P2Y12 Antagonists Inhibit Platelet Activation
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Rap1b activation in response to ADP and other agonists
[28,29,30,31]. However, we have recently shown that the
thrombin mimetic PAR4 peptide AYPGKF and collagen at high
concentrations elicited Rap1b activation in P2Y12 deficient
platelets [22]. AYPGKF-induced, P2Y12-independent, activation
of Rap1b requires Ca2+. Thus, if forskolin inhibits AYPGKF-
induced Ca2+ elevation, it should also inhibit agonist-induced
Rap1b activation in the P2Y12 deficient platelets. Indeed, forskolin
inhibited thrombin- or AYPGKF-induced Rap1b activation in
P2Y12 deficient platelets (Fig. 5C and 5D). In contrast, 2MeSAMP
and Cangrelor did not affect thrombin- or AYPGKF-induced
Rap1b activation in P2Y12 deficient platelets (Fig. 5C and 5D).
These data demonstrate that 2MeSAMP and Cangrelor inhibited
agonist-induced Rap1b activation in a P2Y12-specific manner.
Cangrelor Inhibited Thrombus Formation in Wild-type
but not P2Y12 Deficient Mice
All the above data indicate that the in vitro effects of 2MeSAMP
and Cangrelor on platelets are mediated specifically through
P2Y12. Unlike clopidogrel (Plavix), which is a pro-drug, Cangrelor
is an active drug that does not require metabolic conversion for
activity. Although the CHAMPION clinical trials did not show
clinical benefit of cangrelor beyond that of clopidogrel for
percuataneous coronary interventions [32], the BRIDGE study
of short-term use of Cangrelor prior to surgery recently concluded
with promising results [33]. Thus, it is important to demonstrate
whether or not inhibition of thrombosis in vivo by Cangrelor is
specifically mediated through P2Y12. The role of P2Y12 in in vivo
thrombus formation was evaluated using a FeCl3-induced carotid
artery thrombosis model. No occlusive thrombi formed in P2Y12
deficient mice when low-concentrations of FeCl3 (#10%) were
applied (data not shown). However, when 20% FeCl3 was used to
cause vessel injury, P2Y12 deficient mice were able to initiate
thrombus formation (Fig. 6C). Unlike wild-type mice, in which
occlusive thrombi were formed within 10 minutes (Fig. 6A and
6E), thrombi were repeatedly formed and washed away in 60%
(9 mice out of 15) of the P2Y12 deficient mice examined (Fig. 6C
and 6E). Injection of Cangrelor into wild-type mice inhibited
stable thrombus formation in a manner similar to that observed in
P2Y12 deficient mice (Fig. 6B). In contrast, injection of Cangrelor
failed to affect stable thrombus formation in P2Y12 deficient mice
(Fig. 6D and 6E). These results demonstrate that Cangrelor
mediated inhibition of thrombus formation in vivo is P2Y12
dependent.
Discussion
The purpose of this study was to re-examine the specificity of
the P2Y12 antagonists, Cangrelor and 2MeSAMP in inhibiting
platelet functions. This study was initiated to test the assertion that
Cangrelor and 2MeSAMP do not inhibit platelet activation solely
through a P2Y12-dependent manner. Additionally, we discovered
that inhibition of platelet activation by the cAMP/PKA pathway
Figure 2. 2MeSAMP and Cangrelor failed to stimulate cAMP
production. (A) Washed human platelets were incubated with
2MeSAMP (2Me), Cangrelor (Can), or forskolin (Forsk) at 37uC for
5 min. The reactions were stopped by the addition of an equal volume
of 12% (w/v) trichloroacetic acid. cAMP concentrations were de-
termined by using a cAMP immunoassay kit. Statistical differences were
examined by Student t test. Data are mean 6 SD. *P,0.005 versus
platelets in the absence of antagonists and forskolin. (B) Washed
platelets from P2Y12 deficient mice or wild-type controls were pre-
incubated with 2MeSAMP, Cangrelor, or forskolin for 5 min. The
reactions were stopped by the addition of an equal volume of 12%
(w/v) trichloroacetic acid. cAMP concentrations were determined by
using a cAMP immunoassay kit. Statistical differences were examined by
Student t test. Data are mean 6 SD. *P,0.001 versus platelets of same
genotype in the absence of antagonists and forskolin. (C) Washed
platelets from wild-type mice were pre-incubated with 2MeSAMP,
Cangrelor, or forskolin for 5 min. cAMP concentrations were de-
termined by HPLC electrospray ionization tandem mass spectrometry
as described under Experimental Procedures. Statistical differences were
examined by Student t test. Data are mean 6 SD. *P,0.001 versus
platelets in the absence of antagonists and forskolin.
doi:10.1371/journal.pone.0051037.g002
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involves multiple signaling pathways including PLCb, Akt, and
Rap1b.
Cangrelor and 2MeSAMP have been extensively employed to
identify the role of P2Y12 in platelet activation. However, a recent
study reported that both Cangrelor and 2MeSAMP inhibit platelet
activation by increasing intra-platelet cAMP concentrations
through a P2Y12-independent mechanism [19]. If their data are
correct, any conclusions on the role of P2Y12 in platelet activation
drawn from experiments using these two antagonists need to be re-
evaluated. More importantly, Cangrelor is being evaluated in
clinical trials of thrombotic diseases with promising results [33].
Therefore, it is necessary to understand the detail mechanisms by
which Cangrelor inhibits platelet activation. The key evidence
showing that Cangrelor and 2MeSAMP inhibit platelet activation
via a P2Y12-independent mechanism is that Cangrelor and
2MeSAMP dose-dependently increased intra-platelet cAMP levels
in the absence of agonists. In that study, incubation of platelets
with 0.05 mM of Cangrelor or 5 mM of 2MeSAMP dramatically
increased cAMP concentrations. In contrast, our data indicate that
Cangrelor (#1 mM) and 2MeSAMP (#10 mM) failed to stimulate
cAMP production in both human and mouse platelets. We show
that 1 mM of Cangrelor and 10 mM of 2MeSAMP are sufficient to
inhibit P2Y12 function in isolated platelets (Fig. 1), which are the
levels of those antagonists used to demonstrate the role of P2Y12 in
most platelet studies [8,18,29,30,34,35,36]. The reason for the
discrepancy between our study and the previous report are
unknown. However, we found that 2MeSAMP at high concentra-
tions ($50 mM) apparently increases cAMP concentrations in
platelets. But because these effects were observed when this
compound was added to platelet-free Tyrode’s solution, we suspect
that at high concentrations 2MeSAMP may cross-react with the
antibody used for measurement of cAMP by ELISA and thereby
produce a false positive result. To address this issue, we developed
tandem mass spectrometry method to measure cAMP concentra-
tions. In this highly specific and sensitive assay, neither 2MeSAMP
(50 mM) nor Cangrelor (1 mM) enhanced cAMP concentrations in
platelets or in solution. One difference we noticed between the
previous study [19] and this study in measuring intra-platelet
cAMP is that platelet-rich plasma was used in the previous study
but we used washed platelets. It is not clear whether plasma affects
cAMP measurement. Agents that elevate cAMP are strong
inhibitors of platelet activation [37]. In agreement with the results
that Cangrelor and 2MeSAMP could not induce cAMP pro-
duction in platelets, they failed to inhibit platelet secretion and
aggregation in P2Y12 deficient platelets. In contrast, PGI2 and
forskolin, respectively abolished platelet activation in both wild-
type and P2Y12 deficient mice.
Further evidence supporting the conclusion that Cangrelor and
2MeSAMP are unable to induce P2Y12-independent activation of
the cAMP-PKA pathway in platelets was provided by our study of
VASP phosphorylation. VASP is a well-established substrate for
PKA. Thus, if Cangrelor and 2MeSAMP increase intra-platelet
cAMP concentrations to a level similar as PGI2, they should be
able to induce VASP phosphorylation. However, unlike PGI2 or
forskolin, both Cangrelor and 2MeSAMP, even at high concen-
trations, failed to stimulate VASP phosphorylation in intact
platelets.
Although it is well established that cAMP/PKA signaling
inhibits platelet activation, the mechanisms by which cAMP/PKA
inhibits platelet activation are not fully understood. In this regard,
PKA can phosphorylate glycoprotein (GP) Ibb, resulting in
inhibition of GPIb-IX-V-stimulated platelet activation [38]. PKA
has been shown to phosphorylate PLCb and inhibit PLCb
signaling in COS 7 cells [39]. Ca2+ mobilization from the PLCb
Figure 3. 2MeSAMP and Cangrelor failed to stimulate VASP
phosphorylation in platelets. (A) Washed human platelets were
incubated with 2MeSAMP (2Me), Cangrelor (Can), or forskolin (Forsk) at
37uC for 5 min. The reactions were stopped by adding equal volume of
26SDS sample buffer. Phosphorylation of VASP was detected by
Western blotting with mouse monoclonal antibodies specifically
recognizing the phosphorylated VASP residues Ser239. (B–C) Washed
platelets from wild-type (B) or P2Y12 deficient mice (C) were pre-
incubated with DMSO, forskolin (10 mM), 2MeSAMP (10 mM), or
Cangrelor (1 mM) for 5 min. Reactions were stopped by adding equal
volume of 26SDS sample buffer. Phosphorylation of VASP was detected
by Western blotting with mouse monoclonal antibodies specifically
recognizing the phosphorylated VASP residues Ser157 or Ser239.
doi:10.1371/journal.pone.0051037.g003
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signaling is a key event in platelet activation induced by GPCR
agonists such thrombin and TXA2. Our data indicate that PKA-
dependent inhibition of platelet activation involves the PLCb
pathway, because pre-treatment of platelets with forskolin or PGI2
abolished AYPGKF-elicited Ca2+ elevation (Fig. 4). Thus, if
Cangrelor and 2MeSAMP inhibits platelet activation by in-
creasing cAMP concentrations through P2Y12-independent me-
chanisms, they should be able to inhibit AYPGKF-elicited Ca2+
elevation. However, neither Cangrelor nor 2MeSAMP had an
effect on AYPGKF-stimulated Ca2+ mobilization in P2Y12 de-
ficient platelets.
Forskolin and PGI2, respectively inhibited multiple signaling
pathways that are known to play important roles in mediating
platelet secretion and aggregation, such as Akt phosphorylation
[40] and Rap1b activation [27]. In contrast, Cangrelor and
2MeSAMP had no effect on AYPGKF-stimulated phosphoryla-
tion of Akt and Rap1b activation in P2Y12 deficient platelets.
These data demonstrate that the inhibitory effect of Cangrelor and
2MeSAMP on platelet activation is P2Y12-dependent and does not
involve the P2Y12-independent activation of the cAMP/PKA
pathway.
P2Y12 is not only important for agonist-induced platelet
activation in vitro, but also contributes to thrombosis in vivo
Figure 4. The PKA activators, but not 2MeSAMP and Cangrelor, inhibited Ca2+ mobilization in P2Y12 deficient platelets. Washed
platelets from P2Y12 deficient mice were labeled with 12.5 mM Fura-2/AM/0.2% Pluronic F-127 and resuspended in Tyrode’s solution at 36108/ml.
Platelets were preincubated with Cangrelor (1 mM), 2MeSAMP (10 mM), forskolin (10 mM), or PGI2 (1 mM), and then stimulated with AYPGKF (500 mM).
Changes in the intracellular Ca2+ levels were measured every 2 s and expressed as a ratio of fluorescence (FL) detected at 509 nm emission with an
excitation wavelength of 340 nm and 380 nm (A). Summarized data from three experiments are shown (B). Statistical differences were examined by
Student t test. Data are mean 6 SD. *P,0.001 versus DMSO.
doi:10.1371/journal.pone.0051037.g004
Figure 5. The PKA activators, but not 2MeSAMP and Cangrelor, inhibited Akt phosphorylation and Rap1b activation in P2Y12
deficient platelets. (A-B) Washed platelets from P2Y12 deficient mice were pre-incubated with 2MeSAMP (10 mM) (2Me), Cangrelor (1 mM) (Can), or
forskolin (10 mM) (Forsk) at 37uC for 5 min, and then stimulated with thrombin (0.25 U/ml) (A) or AYPGKF (500 mM) (B). Akt phosphorylation was
detected by Western blotting with a rabbit monoclonal antibody specifically recognizing the phosphorylated Akt residue Ser473 or Thr308. A mouse
monoclonal antibody against b-actin (Sigma-Aldrich) was used to verify equal loading. (C–D) Washed platelets from P2Y12 deficient mice were pre-
incubated with 2MeSAMP (10 mM) (2Me), Cangrelor (1 mM) (Can), or forskolin (10 mM) (Forsk) at 37uC for 5 min, and then stimulated with thrombin
(0.25 U/ml) (C) or AYPGKF (500 mM) (D). GTP-bound Rap1 was precipitated with GST-RalGDS RBD bound to glutathione-agarose beads and detected
by Western blot.
doi:10.1371/journal.pone.0051037.g005
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[8,41]. Using a FeCl3-induced carotid artery thrombosis model,
we found that the initial thrombus formation is not impaired in
P2Y12 deficient mice. However, most P2Y12 deficient mice cannot
form stable thrombi under our experimental conditions. Likewise,
injection of Cangrelor into wild-type mice inhibits stable thrombus
formation. Accordingly, injection of Cangrelor has no effect on
thrombus formation in P2Y12 deficient mice. Initial thrombus
formation caused by vascular injury is mediated by von Will-
Figure 6. Cangrelor inhibited thrombus formation in wild-type but not P2Y12 deficient mice. (A–D) FeCl3-induced carotid artery injury
was performed and time to occlusive thrombus formation recorded as described under Experimental Procedures. Wild-type (A and B) or P2Y12
deficient mice (C and D) were injected with saline (A and C) or Cangrelor (B and D) 5 min prior to the carotid artery injury. (E) Mice were calculated by
time length of forming occlusive thrombi (,10 min, 10–30 min, .30 min). Statistical differences were examined by Fisher exact test.
doi:10.1371/journal.pone.0051037.g006
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ebrand factor bound to subendothelial matrix. Stable thrombus
formation requires integrin activation, a process in which P2Y12
plays an important role. Our results demonstrate that Cangrelor
inhibition of thrombus formation in vivo is also P2Y12 dependent.
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